At the end of 2023, the FDA approved Casgevy for sickle cell disease, its first approval for a therapeutic that used the genome editing tool clustered regulatory interspaced palindromic repeats ...
Researchers shed new light on G-quadruplexes, a type of secondary DNA structure that has attracted attention as a potential therapeutic target in cancer. Every day, billions of cells in your body ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback